Cara Therapeutics (CARA) Tops Q3 EPS by 5c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. SMCI
8. RTX
9. S
10. COF

Go back to Cara Therapeutics (CARA) Tops Q3 EPS by 5c

Cara Therapeutics Reports Third Quarter 2016 Financial Results

November 3, 2016 4:01 PM EDT

 Currently enrolling three late stage studies with CR845 totaling over 900 patients    

 Top line data expected in 1H 2017  

 Conference call today at 4:30 p.m. ET  

STAMFORD, CONN., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced financial results for the third quarter ended September 30, 2016.

We are pleased to be actively enrolling late... More